ArticleCurrent microbiology2026
Differential Roles of Ag and ZnO in the Bactericidal Activity of Ag/ZnO-Hydroxyapatite Nanocomposites against Multidrug-Associated Methicillin-Resistant Staphylococcus aureus.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is often resistant to multiple antibiotic classes and extremely difficult to treat, highlighting the urgent need for new drugs or alternative strategies. Hydroxyapatite (HAp) combined with silver (Ag) and zinc oxide (ZnO) to form an Ag/ZnO-HAp nanocomposite has been widely studied for its antibacterial properties. This nanocomposite is often assumed to produce additive or synergistic antibacterial effects. Four Ag/ZnO-HAp nanocomposites with different Ag-to-ZnO mole ratios: nanocomposite-A (0.005:0.005), nanocomposite-B (0.01:0.005), nanocomposite-C (0.005:0.01), and nanocomposite-D (0.01:0.01) were used to understand the roles of Ag and ZnO in antibacterial activity against MRSA ATCC700699. Agar diffusion tests of nanocomposites A, B, C, and D produced inhibition zones of 8, 9, 6, and 8 mm, respectively, whereas unmodified HAp showed no inhibition zone. Bactericidal assays revealed log reductions of 5.27, 7.16, 5.00, and 5.81 for nanocomposites A, B, C, and D at 0.0625 mg/mL over 18 h, respectively. Specific death rates (min
Indexed as
Identifiers
42632861What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.